Capsianoside III



Compound IDCDAMM01909
Common nameCapsianoside III
IUPAC name2-[[6-[2-[14-[4,5-dihydroxy-6-(hydroxymethyl)-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol
Molecular formulaC50H84O26

Experimental data

Retention time19.52
Adduct[M+2H]2+
Actual mz551.27
Theoretical mz551.272
Error3.4
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.3434

Identifiers and class information

Inchi keyAKJRMUURRHAKDT-DRPMNEMANA-N
SmilesOCC1OC(OC2C(O)C(O)C(OC2OC(C=C)(C)CCC=C(C)CCC=C(C)CCC=C(C)COC3OC(CO)C(O)C(O)C3OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)CO)C(O)C(O)C1O
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Plant source

  • Curcuma longa L.

    • Pharmacokinetic properties

    Number of descriptor values(#stars)19
    Number of non-conjugated amine groups (#amine)0
    Number of amidine and guanidine groups (#amidine)0
    Number of carboxylic acid groups (#acid)0
    Number of non-conjugated amide groups (#amide)0
    Number of rotatable bonds (#rotor)41
    Number of reactive functional groups (#rtvFG)5
    Predicted central nervous system activity (CNS)-2
    Molecular weight (mol_MW)1101.2
    Computed dipole moment(dipole)5.17
    Total solvent accessible surface area (SASA)1463.16
    Hydrophobic component of SASA (FOSA)953.364
    Hydrophilic component of SASA (FISA)504.242
    Pie component of the SASA (PISA)5.553
    Weakly polar component of the SASA (WPSA)0
    Total solvent accesible volume (volume)3022.27
    Number of hydrogen bond donors (donorHB)16
    Number of hydrogen bond acceptors (accptHB)43.25
    Free energy of solvation of dipole (dip^2/V)0.0088427
    Index of cohesive interaction in solids (ACxDN^.5/SA)0.118237
    Globularity descriptor (glob)0.690922
    Predicted polarizability in cubic angstroms (QPpolrz)88.524
    Predicted hexadecane/gas partition coefficient (QPlogPC16)34.255
    Predicted octanol/gas partition coefficient (QPlogPoct)77.111
    Predicted water/gas partition coefficient (QPlogPw)63.698
    Predicted octanol/water partition coefficient (QPlogPo/w)-5.087
    Predicted aqueous solubility (QPlogS)-0.017
    Conformation-independent predicted aqueous solubility (CIQPlogS)-3.134
    Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.56
    Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.164
    Predicted brain/blood partition coefficient (QPlogBB)-8.95
    Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.04
    Predicted skin permeability, log Kp (QPlogKp)-6.857
    PM3 calculated ionization potential (IP(ev))9.292
    PM3 calculated electron affinity (EA(eV))-0.906
    Number of likely metabolic reactions (#metab)25
    Prediction of binding to human serum albumin (QPlogKhsa)-3.747
    Predicted qualitative human oral absorption (HumanOralAbsorption)1
    Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
    Solvent-accessible surface area of fluorine atoms (SAFluorine)0
    Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
    Van der Waals surface area (PSA)400.057
    Number of nitrogen and oxygen atoms (#NandO)26
    Number of violations of Lipinski’s rule of five (RuleOfFive)3
    Number of violations of Jorgensen’s rule of three (RuleOfThree)2

    Compound-target network

    Cytoscape Graph

    Protein targets associated with phytocompound

    Uniprot ID Gene name Target name TTD_ID Prediction source
    P15692VEGFAVascular endothelial growth factor AT20761SEA
    P05230FGF1Acidic fibroblast growth factorT18639SEA
    P09038FGF2Basic fibroblast growth factorT31621SEA
    P17931LGALS3Galectin-3T72038SEA
    P04746AMY2APancreatic alpha-amylaseT86918SEA
    Q99417MYCBPMYCBP messenger RNAT37298SEA

    Target associated diseases

    TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
    T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
    T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
    T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
    T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
    T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
    T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
    T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
    T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
    T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
    T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
    T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
    T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
    T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
    T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP

    Copyright © 2025